iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, tissues, and living cells for their research, with the available biospecimens. Its iSpecimen Marketplace platform solves this problem and transforms the biospecimen procurement process to accelerate medical discovery.
DSS Inc. (NYSE American: DSS) is a multinational company operating business segments in blockchain security, direct marketing, healthcare, consumer packaging, real estate, renewable energy, and securitized digital assets. Its business model is based on a distribution sharing system in which shareholders will receive shares in its subsidiaries as DSS strategically spins them out into IPOs. DSS is led by its seasoned leaders with decades of industry experience.
Medalist Diversified REIT (NASDAQ: MDRR) was founded in 2003 as a private equity company specializing in acquiring, owning, and managing commercial real estate in the Southeast. The Company’s strategy is to focus on value-add and opportunistic commercial real estate which is expected to provide an attractive balance of risk and returns. Medalist utilizes a rigorous, consistent, and replicable process for sourcing and conducting due diligence of acquisitions. The Company seeks to maximize operating performance of current properties by utilizing a hands-on approach to property management while monitoring the middle market real estate markets in the Southeast for acquisition opportunities and disposal of properties as considered appropriate.
Genetic Technologies Limited is a diversified molecular diagnostics company developing tools for the prediction and assessment of chronic disease risk to help physicians proactively manage patient health. The Company’s lead products, ‘GeneType for Breast Cancer’ and ‘GeneType for Colorectal Cancer’, are clinically validated risk assessment tests that are first in their class. The Company signed a multi-year distribution agreement for its COVID-19 Risk Test and remains on track to launch its revolutionary Multi-Test, covering up to 70% of mortalities and morbidities, including major oncological, metabolic, and degenerative diseases. Genetic Technologies recent acquisition of EasyDNA has significantly accelerated the Company’s commercialization strategy, providing established revenue streams and direct-to-consumer marketing channels that include 70 websites in 40 countries. Listed on the ASX in 2000 and NASDAQ in 2005, Genetic Technologies has been a leader in the development and commercialization of genetic risk assessment technology for 20 years.
DeFi Technologies builds and manages assets in the rapidly emerging decentralized financial market, providing institutional and retail investors easy access to previously unseen returns through innovative projects and groundbreaking protocols that are fundamentally reshaping the global financial system.
DeFi Technologies builds and manages assets in the rapidly emerging decentralized financial market, providing institutional and retail investors easy access to previously unseen returns through innovative projects and groundbreaking protocols that are fundamentally reshaping the global financial system.
Marpai is an AI tech company revolutionizing the self-funded health plan
market representing over $1 trillion in health claims, $20 billion in
administrative fees, and 95 million Americans. Just as Netflix, Amazon,
Uber, and Tesla use artificial intelligence to transform and lead industry
sectors, Marpai (pronounced Mar-pay) is using deep learning, the most
advanced artificial intelligence, to transform health plan administration
for companies who self-fund their health plans. As a next-generation
TPA (Third Party Administrator) using SMART technology (deeplearning powered), Marpai’s mission is to save lives, improve lives, and
radically reduce the costs of healthcare for employers and plan
members.
Draganfly has been a leader in the professional drone industry for
more than 20 years, supporting clients with enterprise drone
solutions, contract engineering services, custom software,
professional unmanned aerial vehicle (UAV) services, and
more. From public safety to pop culture, Draganfly has shaped not
just the UAV industry, but the way people around the world work and
live. Breaking ground with international firsts, Draganfly has a legacy
of leading the professional drone industry, including releasing the
first commercialized quadrotor UAV in 1999 and releasing the first
multirotor UAV with an integrated camera system in 2001. In 2013,
Draganflyer was credited as the world’s first small unmanned aerial
system (sUAS) to save a person’s life, and in 2016, Draganfly
became the first company to have multiple UAV systems deemed
Transport Canada Compliant.
Bragg Gaming Group is a next generation gaming group with cutting-edge technology, leading brands and world-class management expertise, developing into a global gaming force. Formed by a team of gaming industry experts, Bragg's main portfolio asset is ORYX Gaming, an innovative business-to-business gaming technology platform and casino content aggregator. Through this brand and targeted acquisitions, Bragg is focused on becoming a leader within the evolving global gaming industry.
DSS Inc. (NYSE American: DSS) is a multinational company operating business segments in blockchain security, direct marketing, healthcare, consumer packaging, real estate, renewable energy, and securitized digital assets. Its business model is based on a distribution sharing system in which shareholders will receive shares in its subsidiaries as DSS strategically spins them out into IPOs. DSS is led by its seasoned leaders with decades of industry experience.
Medalist Diversified REIT (NASDAQ: MDRR) was founded in 2003 as a private equity company specializing in acquiring, owning, and managing commercial real estate in the Southeast. The Company’s strategy is to focus on value-add and opportunistic commercial real estate which is expected to provide an attractive balance of risk and returns. Medalist utilizes a rigorous, consistent, and replicable process for sourcing and conducting due diligence of acquisitions. The Company seeks to maximize operating performance of current properties by utilizing a hands-on approach to property management while monitoring the middle market real estate markets in the Southeast for acquisition opportunities and disposal of properties as considered appropriate.
Genetic Technologies Limited is a diversified molecular diagnostics company developing tools for the prediction and assessment of chronic disease risk to help physicians proactively manage patient health. The Company’s lead products, ‘GeneType for Breast Cancer’ and ‘GeneType for Colorectal Cancer’, are clinically validated risk assessment tests that are first in their class. The Company signed a multi-year distribution agreement for its COVID-19 Risk Test and remains on track to launch its revolutionary Multi-Test, covering up to 70% of mortalities and morbidities, including major oncological, metabolic, and degenerative diseases. Genetic Technologies recent acquisition of EasyDNA has significantly accelerated the Company’s commercialization strategy, providing established revenue streams and direct-to-consumer marketing channels that include 70 websites in 40 countries. Listed on the ASX in 2000 and NASDAQ in 2005, Genetic Technologies has been a leader in the development and commercialization of genetic risk assessment technology for 20 years.
DeFi Technologies builds and manages assets in the rapidly emerging decentralized financial market, providing institutional and retail investors easy access to previously unseen returns through innovative projects and groundbreaking protocols that are fundamentally reshaping the global financial system.
DeFi Technologies builds and manages assets in the rapidly emerging decentralized financial market, providing institutional and retail investors easy access to previously unseen returns through innovative projects and groundbreaking protocols that are fundamentally reshaping the global financial system.
Marpai is an AI tech company revolutionizing the self-funded health plan
market representing over $1 trillion in health claims, $20 billion in
administrative fees, and 95 million Americans. Just as Netflix, Amazon,
Uber, and Tesla use artificial intelligence to transform and lead industry
sectors, Marpai (pronounced Mar-pay) is using deep learning, the most
advanced artificial intelligence, to transform health plan administration
for companies who self-fund their health plans. As a next-generation
TPA (Third Party Administrator) using SMART technology (deeplearning powered), Marpai’s mission is to save lives, improve lives, and
radically reduce the costs of healthcare for employers and plan
members.
Draganfly has been a leader in the professional drone industry for
more than 20 years, supporting clients with enterprise drone
solutions, contract engineering services, custom software,
professional unmanned aerial vehicle (UAV) services, and
more. From public safety to pop culture, Draganfly has shaped not
just the UAV industry, but the way people around the world work and
live. Breaking ground with international firsts, Draganfly has a legacy
of leading the professional drone industry, including releasing the
first commercialized quadrotor UAV in 1999 and releasing the first
multirotor UAV with an integrated camera system in 2001. In 2013,
Draganflyer was credited as the world’s first small unmanned aerial
system (sUAS) to save a person’s life, and in 2016, Draganfly
became the first company to have multiple UAV systems deemed
Transport Canada Compliant.
Bragg Gaming Group is a next generation gaming group with cutting-edge technology, leading brands and world-class management expertise, developing into a global gaming force. Formed by a team of gaming industry experts, Bragg's main portfolio asset is ORYX Gaming, an innovative business-to-business gaming technology platform and casino content aggregator. Through this brand and targeted acquisitions, Bragg is focused on becoming a leader within the evolving global gaming industry.
Medigus Ltd is an Israel-based medical device company. It is engaged in the development, manufacturing, and marketing of surgical endostaplers and direct vision systems for minimally invasive medical procedures. The key product of the company is the MUSE (Medigus Ultrasonic Surgical Endostapler) system is a single-use device for the incisionless treatment of GERD (gastroesophageal reflux disease), which is based on proprietary platform technology and know-how.
Wytec is a designer and developer of 5G networks and has developed intellectual property that can support the development and deployment of public and private 5G cellular networks. Wytec also partners with the world’s top technology providers in both inbuilding cellular and private LTE networks with a strong concentration in the educational industry.
Draganfly has been a leader in the professional drone industry for more than 20 years, supporting clients with enterprise drone solutions, contract engineering services, custom software, professional unmanned aerial vehicle (UAV) services, and more. From public safety to pop culture, Draganfly has shaped not just the UAV industry, but the way people around the world work and live. Breaking ground with international firsts, Draganfly has a legacy of leading the professional drone industry, including releasing the first commercialized quadrotor UAV in 1999 and releasing the first multirotor UAV with an integrated camera system in 2001. In 2013, Draganflyer was credited as the world’s first small unmanned aerial system (sUAS) to save a person’s life, and in 2016, Draganfly became the first company to have multiple UAV systems deemed Transport Canada Compliant.
Newt is a cloud-based Software as a Service (SaaS) platform enabling enterprises to offer digital financial products and services. Digital financial technologies and infrastructure are reshaping payments, commerce, and access to financial services, creating a growing market opportunity for digital financial service disruptors like Newt.
DeFi Technologies builds and manages assets in the rapidly emerging decentralized financial market, providing institutional and retail investors easy access to previously unseen returns through innovative projects and groundbreaking protocols that are fundamentally reshaping the global financial system.
Newt is a cloud-based Software as a Service (SaaS) platform enabling enterprises to offer digital financial products and services. Digital financial technologies and infrastructure are reshaping payments, commerce, and access to financial services, creating a growing market opportunity for digital financial service disruptors like Newt.
Draganfly has been a leader in the professional drone industry for more than 20 years, supporting clients with enterprise drone solutions, contract engineering services, custom software, professional unmanned aerial vehicle (UAV) services, and more. From public safety to pop culture, Draganfly has shaped not just the UAV industry, but the way people around the world work and live. Breaking ground with international firsts, Draganfly has a legacy of leading the professional drone industry, including releasing the first commercialized quadrotor UAV in 1999 and releasing the first multirotor UAV with an integrated camera system in 2001. In 2013, Draganflyer was credited as the world’s first small unmanned aerial system (sUAS) to save a person’s life, and in 2016, Draganfly became the first company to have multiple UAV systems deemed Transport Canada Compliant.
Draganfly has been a leader in the professional drone industry for more than 20 years, supporting clients with enterprise drone solutions, contract engineering services, custom software, professional unmanned aerial vehicle (UAV) services, and more. From public safety to pop culture, Draganfly has shaped not just the UAV industry, but the way people around the world work and live. Breaking ground with international firsts, Draganfly has a legacy of leading the professional drone industry, including releasing the first commercialized quadrotor UAV in 1999 and releasing the first multirotor UAV with an integrated camera system in 2001. In 2013, Draganflyer was credited as the world’s first small unmanned aerial system (sUAS) to save a person’s life, and in 2016, Draganfly became the first company to have multiple UAV systems deemed Transport Canada Compliant.
EVT was founded with a vision of championing the joy of motoring in an electric world. As the planet undergoes an ‘EV revolution’ and becomes more green, we believe some of the ‘joy’ of motoring has been lost along the way in the design and character of early electric vehicle brands that have come to market.
Given this, at EVT our ‘big idea’ is that we can electrify iconic driving experiences, helping iconic, luxury and classic brands go electric. We believe this will help accelerate the EV revolution as drivers who might otherwise be further back on the EV adoption curve can get behind the wheel of beloved brands that we help go electric.
We believe this big idea will create value for our shareholders as we own iconic motoring brands, controlling manufacturing and deriving full value from the total customer experience.
Can-Fite BioPharma Ltd. (NYSE American: CANF) is an advanced clinical stage drug development company with a platform technology that addresses multi-billion-dollar markets in the treatment of autoimmune inflammatory diseases including Rheumatoid Arthritis and Psoriasis, and liver diseases including advanced liver cancer and NASH. Can-Fite’s drugs have an excellent safety profile with experience in over 1,000 patients. Can-Fite’s intellectual property portfolio consists of 13 patent families issued and pending. Piclidenoson and Namodenoson have been out-licensed in select territories with approximately $18 million received to date.
Hut 8 is one of North America's largest innovation-focused digital asset miners, supporting open and decentralized systems since 2018. Located in energy rich Alberta, Canada, Hut 8 has one of the highest installed capacity rates in the industry and holds more self-mined Bitcoin than any crypto miner or publicly traded company globally. The recent deal with Validus Power will add up to 100 megawatts (MW) on top of the 109MW currently in production and aligns with the Company’s sustainable mining goals and ESG investor trends. The Company recently purchased $30 million (one-third of total production) of NVIDIA’s cutting-edge cryptocurrency GPU miners to mine Ethereum and participate in profitable decentralized finance opportunities and will start by getting paid out in Bitcoin, and $44 million of MicroBT miners. Given current bitcoin network dynamics, the hashrates from these installations are expected to increase average production from 6.2 – 7.3 Bitcoin per day to 8 – 10 Bitcoin per day.
This publication includes the deal activity in the insurance sector such as overall highlights, key announced transactions, and the outlook ahead. Read our full report to learn more.
In depth: New financial instruments impairment modelPwC
On June 16, 2016, the FASB issued Accounting Standards Update 2016-13, Financial Instruments – Credit Losses (Topic 326) (the “ASU”). The ASU introduces a new model for recognizing credit losses on financial instruments based on an estimate of current expected credit losses. The new model will apply to: (1) loans, accounts receivable, trade receivables, and other financial assets measured at amortized cost, (2) loan commitments and certain other off-balance sheet credit exposures, (3) debt securities and other financial assets measured at fair value through other comprehensive income, and (4) beneficial interests in securitized financial assets.
Kiromic BioPharma, Inc. is a target discovery and gene-editing company utilizing artificial intelligence and its proprietary neural network platform with a therapeutic focus on immuno-oncology.
A change to the FHA claim filing rule is coming. Learn how you can prepare for it with this joint point of view from PwC's Consumer Finance Group and Financial Services Regulatory Practice.
Dócola is a social good organization with the only free care communication platform that consolidates thousands of free and low-cost patient education resources from the leading nonprofit, government, and commercial organizations in one marketplace. Plus, you can easily create and upload your own resources.
Digital Health: The Smartest Use of Your PhoneMichael Swit
Presentation as part of composite slide deck by panelists at Commercializing Software IP: High Tech, Digital Health & Education, on November 13, 2013, jointly sponsored by UCSF, UC Berkeley, and the Licensing Executives Society (LES)
Medigus Ltd is an Israel-based medical device company. It is engaged in the development, manufacturing, and marketing of surgical endostaplers and direct vision systems for minimally invasive medical procedures. The key product of the company is the MUSE (Medigus Ultrasonic Surgical Endostapler) system is a single-use device for the incisionless treatment of GERD (gastroesophageal reflux disease), which is based on proprietary platform technology and know-how.
Wytec is a designer and developer of 5G networks and has developed intellectual property that can support the development and deployment of public and private 5G cellular networks. Wytec also partners with the world’s top technology providers in both inbuilding cellular and private LTE networks with a strong concentration in the educational industry.
Draganfly has been a leader in the professional drone industry for more than 20 years, supporting clients with enterprise drone solutions, contract engineering services, custom software, professional unmanned aerial vehicle (UAV) services, and more. From public safety to pop culture, Draganfly has shaped not just the UAV industry, but the way people around the world work and live. Breaking ground with international firsts, Draganfly has a legacy of leading the professional drone industry, including releasing the first commercialized quadrotor UAV in 1999 and releasing the first multirotor UAV with an integrated camera system in 2001. In 2013, Draganflyer was credited as the world’s first small unmanned aerial system (sUAS) to save a person’s life, and in 2016, Draganfly became the first company to have multiple UAV systems deemed Transport Canada Compliant.
Newt is a cloud-based Software as a Service (SaaS) platform enabling enterprises to offer digital financial products and services. Digital financial technologies and infrastructure are reshaping payments, commerce, and access to financial services, creating a growing market opportunity for digital financial service disruptors like Newt.
DeFi Technologies builds and manages assets in the rapidly emerging decentralized financial market, providing institutional and retail investors easy access to previously unseen returns through innovative projects and groundbreaking protocols that are fundamentally reshaping the global financial system.
Newt is a cloud-based Software as a Service (SaaS) platform enabling enterprises to offer digital financial products and services. Digital financial technologies and infrastructure are reshaping payments, commerce, and access to financial services, creating a growing market opportunity for digital financial service disruptors like Newt.
Draganfly has been a leader in the professional drone industry for more than 20 years, supporting clients with enterprise drone solutions, contract engineering services, custom software, professional unmanned aerial vehicle (UAV) services, and more. From public safety to pop culture, Draganfly has shaped not just the UAV industry, but the way people around the world work and live. Breaking ground with international firsts, Draganfly has a legacy of leading the professional drone industry, including releasing the first commercialized quadrotor UAV in 1999 and releasing the first multirotor UAV with an integrated camera system in 2001. In 2013, Draganflyer was credited as the world’s first small unmanned aerial system (sUAS) to save a person’s life, and in 2016, Draganfly became the first company to have multiple UAV systems deemed Transport Canada Compliant.
Draganfly has been a leader in the professional drone industry for more than 20 years, supporting clients with enterprise drone solutions, contract engineering services, custom software, professional unmanned aerial vehicle (UAV) services, and more. From public safety to pop culture, Draganfly has shaped not just the UAV industry, but the way people around the world work and live. Breaking ground with international firsts, Draganfly has a legacy of leading the professional drone industry, including releasing the first commercialized quadrotor UAV in 1999 and releasing the first multirotor UAV with an integrated camera system in 2001. In 2013, Draganflyer was credited as the world’s first small unmanned aerial system (sUAS) to save a person’s life, and in 2016, Draganfly became the first company to have multiple UAV systems deemed Transport Canada Compliant.
EVT was founded with a vision of championing the joy of motoring in an electric world. As the planet undergoes an ‘EV revolution’ and becomes more green, we believe some of the ‘joy’ of motoring has been lost along the way in the design and character of early electric vehicle brands that have come to market.
Given this, at EVT our ‘big idea’ is that we can electrify iconic driving experiences, helping iconic, luxury and classic brands go electric. We believe this will help accelerate the EV revolution as drivers who might otherwise be further back on the EV adoption curve can get behind the wheel of beloved brands that we help go electric.
We believe this big idea will create value for our shareholders as we own iconic motoring brands, controlling manufacturing and deriving full value from the total customer experience.
Can-Fite BioPharma Ltd. (NYSE American: CANF) is an advanced clinical stage drug development company with a platform technology that addresses multi-billion-dollar markets in the treatment of autoimmune inflammatory diseases including Rheumatoid Arthritis and Psoriasis, and liver diseases including advanced liver cancer and NASH. Can-Fite’s drugs have an excellent safety profile with experience in over 1,000 patients. Can-Fite’s intellectual property portfolio consists of 13 patent families issued and pending. Piclidenoson and Namodenoson have been out-licensed in select territories with approximately $18 million received to date.
Hut 8 is one of North America's largest innovation-focused digital asset miners, supporting open and decentralized systems since 2018. Located in energy rich Alberta, Canada, Hut 8 has one of the highest installed capacity rates in the industry and holds more self-mined Bitcoin than any crypto miner or publicly traded company globally. The recent deal with Validus Power will add up to 100 megawatts (MW) on top of the 109MW currently in production and aligns with the Company’s sustainable mining goals and ESG investor trends. The Company recently purchased $30 million (one-third of total production) of NVIDIA’s cutting-edge cryptocurrency GPU miners to mine Ethereum and participate in profitable decentralized finance opportunities and will start by getting paid out in Bitcoin, and $44 million of MicroBT miners. Given current bitcoin network dynamics, the hashrates from these installations are expected to increase average production from 6.2 – 7.3 Bitcoin per day to 8 – 10 Bitcoin per day.
This publication includes the deal activity in the insurance sector such as overall highlights, key announced transactions, and the outlook ahead. Read our full report to learn more.
In depth: New financial instruments impairment modelPwC
On June 16, 2016, the FASB issued Accounting Standards Update 2016-13, Financial Instruments – Credit Losses (Topic 326) (the “ASU”). The ASU introduces a new model for recognizing credit losses on financial instruments based on an estimate of current expected credit losses. The new model will apply to: (1) loans, accounts receivable, trade receivables, and other financial assets measured at amortized cost, (2) loan commitments and certain other off-balance sheet credit exposures, (3) debt securities and other financial assets measured at fair value through other comprehensive income, and (4) beneficial interests in securitized financial assets.
Kiromic BioPharma, Inc. is a target discovery and gene-editing company utilizing artificial intelligence and its proprietary neural network platform with a therapeutic focus on immuno-oncology.
A change to the FHA claim filing rule is coming. Learn how you can prepare for it with this joint point of view from PwC's Consumer Finance Group and Financial Services Regulatory Practice.
Dócola is a social good organization with the only free care communication platform that consolidates thousands of free and low-cost patient education resources from the leading nonprofit, government, and commercial organizations in one marketplace. Plus, you can easily create and upload your own resources.
Digital Health: The Smartest Use of Your PhoneMichael Swit
Presentation as part of composite slide deck by panelists at Commercializing Software IP: High Tech, Digital Health & Education, on November 13, 2013, jointly sponsored by UCSF, UC Berkeley, and the Licensing Executives Society (LES)
HAS 20 Virtual: Featuring a World-Class Lineup of Keynote SpeakersHealth Catalyst
The Healthcare Analytics Summit (HAS®) is going virtual this year but will still feature the same world-class experience you expect from HAS–including world-class keynote speakers. HAS 20 Virtual will showcase well-known visionaries and C-level executives from leading healthcare organizations. The summit will feature speakers who’ve battled COVID-19 in the trenches as well as other speakers adjusting to planning for the “new normal” that we all anticipate.
We’re reimagining HAS 20 in a virtual format that will be unlike any other healthcare conference you may have attended, virtual or otherwise. HAS 20 Virtual takes place September 1-3, 2020 and will feature nationally recognized keynote speakers, educational breakout sessions, and much more.
In the latest issue of HealthCare Everything, ‘10 Best Companies in Digital Therapeutics Market 2023,’ We explore Best Companies in the Digital Therapeutics Market.
Top 10 Influential Healthcare Leaders of The Year, 2022.pdfinsightscare
latest edition of Insights Care, “Top 10 Influential Healthcare Leaders of The Year, 2022,” features the fascinating stories of the healthcare leaders who are striving towards enabling advancements by enhancing healthcare services.
Held each year in Boston, Medical Informatics World connects more than 400 healthcare, biomedical science, health informatics, and IT leaders to navigate emerging trends and opportunities in the evolving industry. The event responds to the challenges in collaborating and maximizing the benefit of enabling technologies with inspiring plenary keynotes combined with focused expert-led presentations and discussions. Coverage includes population health management, predictive analytics, payer-provider-pharma data collaborations, patient care and engagement, mobile and wearable technologies, care delivery models, enterprise hospital information systems, clinical decision support, error and readmission reduction, and healthcare data security. The 2015 program features six conference tracks, two interactive dinner workshops and six plenary keynote presentations, providing attendees with the connections, tools and strategies for taking their research and care delivery to the next level. Learn more at http://www.medicalinformaticsworld.com
Lantern Pharma is a clinical stage biotechnology company focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic date to streamline the drug development process and to identify patients who will benefit from their targeted oncology therapies. Their portfolio of therapies consists of compounds that others have tried, but failed, to develop into an approved commercialized drug. Additionally, they develop new compounds with the assistance of their A.I. platform (RADR) and biomarker driven approach. The Company is currently developing four therapeutic programs.
HealthXL is the global clearing house for innovation in healthcare. We catalyse collaboration between leading brands in healthcare and the most exciting tech companies to improve the lives of millions of people.
Together with our partners we establish audacious goals (Moonshots) to work towards within healthcare. Then we search for innovators in digital health that can work with us and our partners to achieve those Moonshots. We help them find each other, create business partnerships and facilitate their relationship through collaboration.
Our partners are Bupa, Cleveland Clinic, Becton Dickinson, IBM, ICON, ResMed, Janssen Healthcare Innovation, Linde Healthcare, Novartis, Partners HealthCare, Silicon Valley Bank, EY, SoftServe, and Hermitage Medical Clinic.
Based in Ann Arbor, Michigan, Zomedica is a veterinary health company creating diagnostic and therapeutic products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. With modest cash burn and a strong balance sheet, including $142.4 million cash and cash equivalents as of June 30, 2023, Zomedica is well-positioned to fund both organic growth and acquisitions.
INNO HOLDINGS INC. is an innovative building-technology company with a mission to transform the construction industry with our proprietary cold-formed steel- framing technology and other building innovations
Everything Blockchain builds platforms of trust for the modern enterprise and is on a mission to ensure every organization has access to the tools and platforms that enable them to manage, store, and protect data without the cost and complexity that holds them back today. The Company’s patented advances in engineering deliver the essential elements needed for real-world business use: speed, security, and efficiency. Everything Blockchain’s current business lines include: EB Advise, Build DB and EB Control.
ASP Isotope is an isotope enrichment company utilizing technology developed in South Africa over the past 20 years to enrich isotopes of elements or molecules with low atomic masses. Many of these elements are unsuitable for enrichment using traditional methods such as centrifuges. The Company’s initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries.
MDNA Life Sciences is a pioneer in the science of mitochondrial DNA. It’s our mission to create an extensive portfolio of proprietary tests that dramatically improve diagnosis, treatment, prognosis and monitoring. Putting an end to the unnecessary surgical procedures, pain and uncertainty that affect patients across the world.
Digital Ally, Inc. is a diversified holding company with operations in video solution technology, human and animal health protection products, healthcare revenue cycle management, ticket brokering and marketing, and event production. The Company pursues an acquisition strategy that targets organizations with positive earnings, strong growth potential, innovation, and operational synergies. To maximize long-term shareholder value, Digital Ally intends to spin-off its ticketing and entertainment business lines into a separate public company in 2023. The spin-off will create two optimized, tech-driven public companies with strong growth opportunities and operating metrics.
Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 25 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies including eleven cancer indications and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0-2.0 million per program.
Sharps Technology is a medical device and pharmaceutical packaging company specializing in the development and manufacturing of innovative drug delivery systems. The Company’s product lines focus on low waste and ultra-low waste syringe technologies that incorporate both passive and active safety features. These features protect front line healthcare workers from life-threatening needle stick injuries and protect the public from needle re-use. Sharps Technology has extensive expertise in specialized prefilled syringe systems and is on track to launch this new product line in Q4 2023. The Company has a manufacturing facility in Hungary and has partnered with Nephron Pharmaceuticals to expand its manufacturing capacity in the US.
Aditxt is a global innovation company focused on discovering and developing precision medicine innovations and deploying them into high-performing businesses. Aditxt’s diverse innovation portfolio includes: Adimune™, Inc., developing and designing a new class of therapeutics for retraining the immune system to address organ rejection, autoimmunity, and allergies; Adivir™, Inc., focused on identifying, developing and commercializing new ways to treat infectious diseases; and Pearsanta™, Inc., offering convenient, rapid, personalized, and high-quality lab testing —anytime and anywhere at its CLIA certified and CAP accredited clinical laboratory based in Richmond, VA.
1847 Holdings LLC, a publicly traded diversified acquisition holding company, was founded by Ellery W. Roberts, a former partner of Parallel Investment Partners, Saunders Karp & Megrue and Principal of Lazard Freres Strategic Realty Investors. EFSH's investment thesis is that capital market inefficiencies have left the founders and/or stakeholders of many small business enterprises and lower-middle market businesses with limited exit options, despite the intrinsic value of their business. Given this dynamic, EFSH can consistently acquire "solid" businesses for reasonable multiples of cash flow and then deploy resources to strengthen the infrastructure and systems to improve operations. These improvements may lead to a sale or IPO of an operating subsidiary at considerably higher valuations than the purchase price (as successfully demonstrated with the mid-2020 IPO of 1847 Goedeker on the NYSE American) and/or alternatively, an operating subsidiary may be held in perpetuity and contribute to EFSH's ability to pay regular and special dividends to shareholders.
Sharps Technology is a medical device and pharmaceutical packaging company specializing in the development and manufacturing of innovative drug delivery systems. The Company’s product lines focus on low waste and ultra-low waste syringe technologies that incorporate both passive and active safety features. These features protect front line healthcare workers from life-threatening needle stick injuries and protect the public from needle re-use. Sharps Technology has extensive expertise in specialized prefilled syringe systems and is on track to launch this new product line in Q4 2023. The Company has a manufacturing facility in Hungary and has partnered with Nephron Pharmaceuticals to expand its manufacturing capacity in the US.
SPI Energy is a global renewable energy company and provider of solar storage and electric vehicle (EV) solutions that was founded in 2006 in Roseville, California and is headquartered in McClellan Park, California. The Company has three core divisions: SolarJuice which has solar wholesale distribution, as well as residential solar and roofing installation and solar module manufacturing (Solar4America & SEM Wafertech), SPI Solar and Orange Power which operates a commercial & utility solar division, and the EdisonFuture/Phoenix Motor EV division. SolarJuice is the leader in renewable energy system solutions for residential and small commercial markets and has extensive operations in the Asia Pacific and North America markets. The SPI Solar commercial & utility solar division provides a full spectrum of EPC services to third party project developers, and develops, owns and operates solar projects that sell electricity to the grid in multiple regions, including the U.S., U.K., and Europe. Phoenix Motor is a leader in medium-duty commercial electric vehicles, and is developing EV charger solutions, electric pickup trucks, electric forklifts, and other EV products. SPI maintains global operations in North America, Australia, Asia and Europe and is also targeting strategic investment opportunities in fast growing green energy industries such as battery storage, charging stations, and other EVs which leverage the Company's expertise and substantial solar cash flow.
BullFrog AI is a technology enabled drug development company using machine learning to usher in a new era of precision medicine. Through its collaborations with leading research institutions, including Johns Hopkins University and J. Craig Venter Institute, BullFrog AI is at the forefront of AI-driven drug development. Using its proprietary bfLEAP™ artificial intelligence platform, BullFrog AI aims to enable the successful development of pharmaceuticals and biologics by predicting which patients will respond to therapies in development. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may have otherwise not received the therapies they need.
BullFrog AI is a technology enabled drug development company using machine learning to usher in a new era of precision medicine. Through its collaborations with leading research institutions, including Johns Hopkins University and J. Craig Venter Institute, BullFrog AI is at the forefront of AI-driven drug development. Using its proprietary bfLEAP™ artificial intelligence platform, BullFrog AI aims to enable the successful development of pharmaceuticals and biologics by predicting which patients will respond to therapies in development. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may have otherwise not received the therapies they need.
BioVie is a clinical-stage company developing what it believes will be transformative therapies to overcome unmet medical needs in neurodegeneration and liver disease. The Company is developing NE3107 for Alzheimer’s (AD) and Parkinson’s (PD) and BIV201 for refractory ascites and HRS-AKI.
Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 25 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies including eleven cancer indications and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0-2.0 million per program.
Genetic Technologies is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GENE offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products.
Splash Beverage Group, an innovator in the beverage industry, owns a growing portfolio of alcoholic and non-alcoholic beverage brands including Copa di Vino wines by the glass, SALT naturally flavored tequilas, Pulpoloco Sangria, and TapouT performance hydration and recovery drinks and TapouT Cognitive Energy Drink. Splash’s strategy is to rapidly develop early-stage brands already in its portfolio as well as acquire and then accelerate brands that have high visibility or are innovators in their categories. Led by a management team that has built and managed some of the top brands in the beverage industry and led sales from product launch into the billions, Splash is rapidly expanding its brand portfolio and global distribution.
Splash Beverage Group, an innovator in the beverage industry, owns a growing portfolio of alcoholic and non-alcoholic beverage brands including Copa di Vino wines by the glass, SALT naturally flavored tequilas, Pulpoloco Sangria, and TapouT performance hydration and recovery drinks and TapouT Cognitive Energy Drink. Splash’s strategy is to rapidly develop early-stage brands already in its portfolio as well as acquire and then accelerate brands that have high visibility or are innovators in their categories. Led by a management team that has built and managed some of the top brands in the beverage industry and led sales from product launch into the billions, Splash is rapidly expanding its brand portfolio and global distribution.
BullFrog AI is a technology enabled drug development company using machine learning to usher in a new era of precision medicine. Through its collaborations with leading research institutions, including Johns Hopkins University and J. Craig Venter Institute, BullFrog AI is at the forefront of AI-driven drug development. Using its proprietary bfLEAP™ artificial intelligence platform, BullFrog AI aims to enable the successful development of pharmaceuticals and biologics by predicting which patients will respond to therapies in development. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may have otherwise not received the therapies they need.
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
Antibiotic Stewardship by Anushri Srivastava.pptxAnushriSrivastav
Stewardship is the act of taking good care of something.
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
WHO launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS) in 2015 to fill knowledge gaps and inform strategies at all levels.
ACCORDING TO apic.org,
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
ACCORDING TO pewtrusts.org,
Antibiotic stewardship refers to efforts in doctors’ offices, hospitals, long term care facilities, and other health care settings to ensure that antibiotics are used only when necessary and appropriate
According to WHO,
Antimicrobial stewardship is a systematic approach to educate and support health care professionals to follow evidence-based guidelines for prescribing and administering antimicrobials
In 1996, John McGowan and Dale Gerding first applied the term antimicrobial stewardship, where they suggested a causal association between antimicrobial agent use and resistance. They also focused on the urgency of large-scale controlled trials of antimicrobial-use regulation employing sophisticated epidemiologic methods, molecular typing, and precise resistance mechanism analysis.
Antimicrobial Stewardship(AMS) refers to the optimal selection, dosing, and duration of antimicrobial treatment resulting in the best clinical outcome with minimal side effects to the patients and minimal impact on subsequent resistance.
According to the 2019 report, in the US, more than 2.8 million antibiotic-resistant infections occur each year, and more than 35000 people die. In addition to this, it also mentioned that 223,900 cases of Clostridoides difficile occurred in 2017, of which 12800 people died. The report did not include viruses or parasites
VISION
Being proactive
Supporting optimal animal and human health
Exploring ways to reduce overall use of antimicrobials
Using the drugs that prevent and treat disease by killing microscopic organisms in a responsible way
GOAL
to prevent the generation and spread of antimicrobial resistance (AMR). Doing so will preserve the effectiveness of these drugs in animals and humans for years to come.
being to preserve human and animal health and the effectiveness of antimicrobial medications.
to implement a multidisciplinary approach in assembling a stewardship team to include an infectious disease physician, a clinical pharmacist with infectious diseases training, infection preventionist, and a close collaboration with the staff in the clinical microbiology laboratory
to prevent antimicrobial overuse, misuse and abuse.
to minimize the developme
ICH Guidelines for Pharmacovigilance.pdfNEHA GUPTA
The "ICH Guidelines for Pharmacovigilance" PDF provides a comprehensive overview of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines related to pharmacovigilance. These guidelines aim to ensure that drugs are safe and effective for patients by monitoring and assessing adverse effects, ensuring proper reporting systems, and improving risk management practices. The document is essential for professionals in the pharmaceutical industry, regulatory authorities, and healthcare providers, offering detailed procedures and standards for pharmacovigilance activities to enhance drug safety and protect public health.
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...The Lifesciences Magazine
Deep Leg Vein Thrombosis occurs when a blood clot forms in one or more of the deep veins in the legs. These clots can impede blood flow, leading to severe complications.
2. This presentation may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are characterized by future or
conditional verbs such as “may,” “will,” “expect,” “intend,” “anticipate,” believe,” “estimate” and “continue” or similar words. You should read
statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future
results of operations or financial condition or state other forward-looking information. Such statements are only predictions and our
actual results may differ materially from those anticipated in these forward-looking statements.
We believe that it is important to communicate future expectations to investors. However, there may be events in the future that we are
not able to accurately predict or control. Factors that may cause such differences include, but are not limited to, those discussed under
Risk Factors in our registration statement and other filings filed with the Securities and Exchange Commission (the "SEC"), including the
uncertainties associated with our lack of profitability, our continued capital needs, our lack of a long operating history, our growth
strategy, the COVID-19 pandemic and its continued impact on the business, our technology development plans, and the regulatory
environment in which we operate. We do not assume any obligation to update forward-looking statements as circumstances change.
Certain market data information in this presentation is based on management's estimates. We obtained the industry, market and
competitive position data used throughout this presentation from internal estimates and research as well as from industry publications
and research, surveys and studies conducted by third parties. We believe our estimates to be accurate as of the date of this
presentation. However, this information may prove to be inaccurate because of the method by which we obtained some of the data for
our estimates or because this information cannot always be verified due to the limits on the availability and reliability of raw data, and
the nature of the data gathering process.
You may access our SEC filings by visiting SEC’s website at http://www.sec.gov. This presentation does not constitute an offer or
invitation for the sale or purchase of securities or to engage in any other transaction with us or our affiliates. The information in this
presentation is not targeted at the residents of any particular country or jurisdiction and is not intended for distribution to, or use by,
any person in any jurisdiction or country where such distribution or use would be contrary to local law or regulation.
Forward Looking Statements
2
3. Christopher Ianelli, MD PhD| Chief Executive Officer, President, and Director
Dr. Ianelli has been serving as our Chief Executive Officer, President, and Director since founding iSpecimen in July 2009. Dr. Ianelli served as Chief
Executive Officer of Abkine Pharmaceuticals, Inc. Dr. Ianelli served as Managing Director at Leerink Partners (formerly Leerink Swann), a leading
healthcare and life science investment bank, where he managed the expansion and delivery of services and directed strategy to develop new
healthcare data and information assets for the firm from August 2003 to March 2008. Prior to that, Dr. Ianelli was a co-founder and Managing
Director of Boston Medical & Scientific Advisors, a healthcare investment research firm. Dr. Ianelli received his Bachelor of Science degree in
Biological Sciences from University of Lowell and both his Ph.D. in Immunology and his M.D. from Tufts University. He completed his residency
training, including a year as Chief Resident, in Pathology at Brigham & Women’s Hospital and Harvard Medical School.
Jill Mullan | Chief Operating Officer, Secretary, Treasurer, and Director
Ms. Mullan has been serving as our Chief Operating Officer since August 2013, Secretary since November 2012, Treasurer since February 2017,
and Director since October 2014. She joined the Company in 2010 as the Vice President of Marketing. From 2003 to 2010, she was a marketing
and business strategy consultant to various technology-based companies including EMC, AppNeta, and Planon Software. From 2000 to 2003,
Ms. Mullan was on the founding team and Director of Marketing at Storigen Systems, a provider of distributed storage networks. She was also
employed at Avid Technology from 1996 to 2000, most recently as a Director of Product Marketing and Management with product responsibility
for Avid’s editing product line. Prior to that, she worked at IBM, MIPS, and Hewlett Packard. She graduated with distinction from Cornell University
with a Bachelor of Science in electrical engineering and received a Masters of Business Administration from Stanford University with a focus on
entrepreneurship and marketing.
Tracy Curley | Chief Financial Officer
Ms. Curley brings three decades of experience in public accounting and corporate finance for both publicly traded companies and emerging
companies like iSpecimen and joined iSpecimen in August 2020. She came to iSpecimen after over a decade with national accounting firms such
as CohnReznick where she focused on serving clients in the middle markets. During her time as a partner in public accounting firms, she was
responsible for creating and leading teams to provide audit and consulting services to a growing clientele of private and public emerging growth
companies primarily in the technology and life sciences industries. Ms. Curley received her Master of Accountancy and Bachelor of Science in
Business Administration with a concentration in accounting from Kansas State University. She also attended the United States Military Academy.
She is a certified public accountant licensed in the Commonwealth of Massachusetts.
Benjamin Bielak | Chief Information Officer
Mr. Bielak has been serving as our Chief Information Officer since June 2018. He served as the Chief Information Officer at GNS Healthcare, a
leading casual machine learning product and services company, from January 2017 to May 2018 and as Director of Academic Technology at
Harvard University, from February 2015 to January 2017. Prior to his work at GNS and Harvard, Mr. Bielak was the Chief Information Officer at
Dovetail Health from November 2006 to April 2014. He previously held roles as Manager of Development and Integration at Boston Medical
Center and Senior Manager of Technology at Sapient, a global services company, from December 1997 to July 2005. Mr. Bielak holds a Masters of
Business Administration degree from Bentley University, where his studies focused on change management, and a master’s degree from Boston
University in computer science.
Management Team
3
4. Investor Highlights
4
180+
Healthcare Provider /Supplier
Organizations
~350
Customer
Organizations
1. Early-stage opportunity with a first mover
advantage
2. $3B-$4B global biospecimen market growing
at 10-15% per year1
3. Unique two-sided marketplace disrupting
the biospecimen procurement process
4. 90% year-over-year revenue growth (2019-
2020)
5. Growing data asset that’s a key enabler and
differentiator
1 “Sources Cited” page 27
5. Accelerate scientific discovery in
an online marketplace that
empowers researchers to instantly
search for and gain access to
patients, biospecimens, and
data across a global network of
healthcare providers
Our Vision
5
6. Human Biospecimens are Essential for Life Science R&D
Basic Research
Biomarker
Identification &
Validation
Drug Discovery &
Development
Diagnostics
Discovery &
Validation
Biofluids
Solid Tissue
Stem & Immune Cells
Plasma,Serum,Urine,Saliva Industry
Academia
Government
6
Lung, Breast,Colon,Brain
BoneMarrow,Blood,Tonsils,
LymphNodes
Applications
Patients
SUPPLY
HEALTHCARE PROVIDERS
DEMAND
LIFE SCIENCE RESEARCHERS
Biospecimens Data Organizations
Medical
Record
7. 10 - 15% Annual Growth
Fueled by precision and regenerative
medicine research 2
Disconnected
MarketParticipants
inNeedofa
MarketplaceSolution
With an Inefficient
Supply Chain
Manual processes plus fragmentation make
it ripe for an online marketplace solution
Large and Inefficient
Biospecimen Market
$3 - $4 Billion
Worldwide yearly spend on human
biospecimen procurement 1
7
1, 2 “Sources Cited” page 27
8. Market Inefficiencies
PROVIDER RESEARCHER
Scientist /
Informaticist
Procurem
ent
Legal &
Compliance
IT /
Informaticist
Scientist & Informaticist
Legal &
Compliance
IT / Informaticist
Researcher &
Procurement
Legal &
Compliance
Principal
Investigator
& Specimen
Operations
PATIENTS PROVIDERS RESEARCHERS
8
Difficulties Connecting, Searching, and Compliantly Transacting
6-12 months on average to develop relationships, requiring the involvement of many stakeholders 3
3 “Sources Cited” page 27
9. Inefficiencies Lead to Losses
Providers miss revenue and
research opportunities
> 3 Billion
clinical specimens are discarded
annually worldwide 5
> 1 Billion
Patient encounters yearly in the U.S. where a
specimen could be provided for research 4
> 800 Million
banked specimens are in biorepository
inventories worldwide 6
9
Researchers limit
their work
… in 2019, 82%
of researchers limit the scope of their work due
to shortage of quality biospecimens 8
“Challenging” and “Frustrating”
most common words used to describe biospecimen
procurement process by researchers 8
10 years ago, 81%
of researchers said they limit the scope of their work
due to difficulties obtaining biospecimens 7
4,5,6,7,8 “Sources Cited” page 27
10. The iSpecimen Marketplace Solution
10
PROVIDER
Procurement
Principal Investigator
/ Operations
IT / Informaticist
PATIENTS
Legal &
Compliance
IT / Informaticist
Researcher &
Procurement
Legal & Compliance
Principal
Investigator
& Specimen
Operations
Scientist & Informaticist
Blood / Pheresis Centers
Clinical Labs
Biorepositories
Pathology Labs
RESEARCH
PATHWAY
CLINICAL
PATHWAY
Industry
Academia
Government
RESEARCHERS
An Online Platform That Instantly Connects Researchers to a Global Network
of Patients, Biospecimens, and Data to Accelerate Time to Discovery
Saves monthsintheaverage biospecimenprocurementprocess
PROVIDERS
Healthcare
Data
11. Full-Service Procurement
We not only Connect Suppliers and Customers, but
We also Manage the Entire Procurement Process
Clickto See the OverviewVideo
SPECIMEN SEARCH & SELECTION
SPECIMEN LOGISTICS
SPECIMEN MANAGEMENT
DATA MANAGEMENT
STUDY/ORDER MANAGEMENT
SUPPLIER SITE TRAINING
COLLECTION KIT BUILDING
COMPLIANCE MANAGEMENT
STUDY DESIGN & SPECIFICATION
CONTRACTING
11
https://pages.ispecimen.com/rs/473-GLR-825/images/ISPCintro.mp4
12. Suppliers and Researchers Benefit
Advance Discovery
Support research mission and advance
diagnostic, therapeutic, and vaccine research
Increase Revenue
Instantly connect to a global network of
researchers
Ensure Compliance
On a platform that protects the privacy and security
of patient information
Accelerate Research
Search for specimens anytime, anywhere, through
our easy-to-use online marketplace
Save Money
Instantly connect to a global network of specimen
providers
Reduce Risk
On a platform that manages contracting
and regulatory compliance
Providers… Researchers…
12
13. 13
34
66
102
147
181
189
2015 2016 2017 2018 2019 2020 March 31,
2021
Growing Supplier Adoption
700+
Hospitals
Also includes three Healthcare Information Exchanges
69% CAGR
Number of Suppliers
(2015-2020)
WORLDWIDE COVERAGE
UnitedStates
UnitedKingdom
Germany
France
Ukraine
Georgia
Bulgaria
RussianFederation
India
Peru
DominicanRepublic
Jamaica
Unique Supplier Organizations Under Agreement
2015– March31,2021
Unique Supplier Organizations ProvideAccess to:
000’s
Clinics and Practice Groups
~50
Biorepositories
125+
Clinical Research Centers
~45
Clinical and Pathology Labs
~5
Blood Centers
13
14. 43 58
559
1,332
2,271
3,241
3,510
2015 2016 2017 2018 2019 2020 March 31,
2021
Unique Customer Organizations with Purchases
2015– March31,2021
69% CAGR
Customers
(2015-2020)
Registered Research Users on the iSpecimen Marketplace
2015– March31,2021
137% CAGR
Registered Users
(2015-2020)
Growing Researcher Adoption
70% of the Top 20 Pharma Companies and 70% of the Top 20 IVD Companies Worldwide
are iSpecimen customers
are iSpecimen customers
150,000+ Specimens Across ~2,000 Projects
delivered to our customers
14
24
69
135
172
230
330
349
2015 2016 2017 2018 2019 2020 March 31,
2021
16. “Utilization of sample data for
research and for monetization is
the next key value driver for
the biobanks.”
- Frost & Sullivan, Global Biobanking Market
Landscape
Rich Data is Our Key
Differentiator
Banked Specimen
Records
Patient
Records
Medical Condition
Records
Clinical
Specimen Records
Laboratory Test
Records
Millions of Unique Specimen
and Patient Records are
searchable on our platform now
and available for future adjacent
opportunities such as patient
search, clinical trial recruitment,
and data licensing.
66M+
16
1M+
12M+
890K
525M+
17. $4.3M
$8.2M
2019 2020
$1.7M
$3.0M
March 31, 2020 March 31, 2021
Statements of Operations Information
For the Three Months Ended March 31, For the Years Ended December 31,
2021
(unaudited)
2020
(unaudited)
2020 2019
Revenue $ 2,963,807 $ 1,711,660 $ 8,184,106 $ 4,298,350
Operating Expenses
Cost of Revenue 1,623,651 654,268 3,585,477 2,127,900
Technology 409,951 426,712 1,426,473 993,329
Sales and Marketing 529,387 431,640 1,775,347 1,413,059
Supply Development 111,576 114,605 495,967 792,778
Fulfillment 269,096 215,171 853,450 914,633
General and Administrative 962,790 314,797 2,453,772 1,936,740
Total Operating Expenses 3,906,451 2,157,193 10,590,486 8,178,439
Loss from Operations (942,644) (445,533) (2,406,380) (3,880,089)
Other Income (Expense), Net
Interest Expense (853,147) (587,669) (2,096,795) (1,724,450)
Change in Fair Value of Derivative Liability –
Convertible Notes (154,000) (605,000) (159,000) 551,000
Change in Fair Value of Derivative Liability – Bridge
Notes (48,000) --- --- ---
Loss on Extinguishment – Bridge Notes (2,750,171) --- --- ---
Gain on Extinguishment – Note Payable 788,156 --- --- ---
Other Income (3,732) --- 9,654 168,859
Interest Income 47 223 437 630
Other Expense, Net (3,020,847) (1,192,446) (2,245,704) (1,003,961)
Loss Before Benefit From Income Taxes (3,963,491) (1,637,979) (4,652,084) (4,884,050)
Benefit from Income Taxes --- --- --- 157,000
Net Loss $ (3,963,491) $ (1,637,979) $ (4,652,084) $ (4,727,050)
17
Revenue (2019 vs. 2020)
90%
Revenue (1Q20 vs. 1Q21)
73%
18. As of March 31, 2021
Assets (unaudited)
Cash and Cash Equivalents $ 355,126
Accounts Receivable - Unbilled 1,079,734
Accounts Receivable, Net 580,196
Due from factor 495,735
Prepaid Expenses and Other Current Assets 428,084
Tax Credit Receivable, Current Portion 179,376
Property, Plant, and Equipment, Net 64,459
Internally Developed Software, Net 2,613,444
Security Deposits 27,601
Total Assets $ 5,823,755
Liabilities
Accounts Payable $ 2,091,562
Accrued Expenses 1,119,322
Accrued Interest 4,253,987
Convertible Notes Payable 5,491,899
Derivative Liabilities for Embedded Conversion – Convertible Notes 2,527,000
Bridge Notes Payable, Net of Debt Discount 4,185,172
Bridge Notes Payable, Related Parties, Net of Debt Discount 1,735,094
Derivative Liability for Embedded Conversion – Bridge Notes 3,662,000
Deferred Revenue 804,065
Total Liabilities 25,870,101
Total Convertible Preferred Stock 11,173,076
Total Stockholders Deficit (31,219,422)
Total Liabilities, Convertible Preferred Stock and Stockholders Deficit $ 5,823,755
Balance Sheet Information
18
19. Investor Summary
180+ Supplier and
~350 Customer
Organizations
150,000+ Specimens
Delivered
66,000,000+
Specimen Records in the
iSpecimen Marketplace
19
1. Early-stage opportunity with a first mover
advantage
2. $3B-$4B global biospecimen market growing
at 10-15% per year1
3. Unique two-sided marketplace disrupting
the biospecimen procurement process
4. 90% year-over-year revenue growth (2019-
2020)
5. Growing data asset that’s a key enabler and
differentiator
20. CONNECT. INNOVATE.
Sign up for free iSpecimen Marketplace account at www.ispecimen.com
CONTACT US
iSpecimen Inc.
450 Bedford Street
Lexington, MA 02420
investors@ispecimen.com
ispecimen.com
22. Strategic Evolution
PHASE 3
Expansion via the Online iSpecimen
Marketplace™
START UP
Company Ideation and Self-
Funding
PHASE 1
Proof of Concept
PHASE 2
Critical Mass of Suppliers and
Early Customer Adoption
2010 – 2011 2012 – 2013 2014 – 2017 2018 – March 31, 2021
0
Customers
1
Supplier Agreement
0
Specimen Records
0
Patient Records
0
FTEs
$500K
Friends and Family Covert. Debt
1
Customer
3
Supplier Agreements
2+ Million
Specimen Records
400+ Thousand
Patient Records
7
FTEs
$2.5M
Series A
140+
Customers
60+
Supplier Agreement
26+ Million
Specimen Records
5+ Million
Patient Records
33
FTEs
$8M
Series B
~350
Customers
180+
Supplier Agreement
66+ Million
Specimen Records
12+ Million
Patient Records
46
FTEs
$12.5M
Debt 9
22
9 Debt as of 6/1/2021
24. to View Initial Results
View Case Cards to See Specimens
that Meet Criteria
24
iSpecimen Marketplace UI/UX
25. Refine Search Results Using Sliders and Check Boxes
Add Specimens to the Cart
iSpecimen Marketplace UI/UX
25
26. View Cart and Add More Specimens
Request a Quote
iSpecimen Marketplace UI/UX
26
Track and Manage Requests
27. 27
Page Note Source Cited
7 1 iSpecimen estimates based on In Vitro Diagnostics Market Size, Share & Trends Analysis Report By Product, By Application, By
Technology (Immunochemistry, Molecular Diagnostics) By End-use, By Region, And Segment Forecasts, 2021 – 2027. Grandview
Research, January 2021; and World Preview 2020,Outlook to 2026. EvaluatePharma, July 2020.
7 2 Global Marketing Insights, Precision Medicine Market Size By Technology (Big Data Analytics, Bioinformatics, Gene Sequencing,
Drug Discovery, Companion Diagnostics), By Application (Oncology, Immunology, CNS, Respiratory), By End-use (Pharmaceutical
Companies, Diagnostic Companies, Healthcare IT companies), Industry Analysis Report, Regional Outlook, Application Potential,
Competitive Market Share & Forecast, 2020-2026, Feb. 2020. and
Regenerative Medicine Market Size, Share and Industry Analysis by Product (Cell Therapy, Gene Therapy, Tissue Engineering,
Platelet Rich Plasma), By Application (Orthopaedics, Wound Care, Oncology), By Distribution Channel (Hospitals, Clinics) & Regional
Forecast, 2019 – 2026. Fortune Business Insight, 2019.
8 3 Frost & Sullivan, Global Biobanking Market Landscape. May 20, 2020, page 357.
9 4 Centers for Disease Control, https://www.cdc.gov/nchs/data/ahcd/namcs_summary/2016_namcs_web_tables.pdf
9 5 iSpecimen estimates based upon American Association of Clinical Chemistry US lab test data cited at
https://www.360dx.com/research-funding/aacc-calls-congress-fund-clinical-lab-training-programs, 2020; and Clinical Lab Services,
Global Market Trajectory and Analytics; Global Industry Analysts report, 2020.
9 6 iSpecimen estimate based upon Henderson, G.E., Cadigan, R.J., Edwards, T.P. et al. Characterizing biobank organizations in the U.S.:
results from a national survey, 2013; and Puchois, Comprehensive Biomarker Discovery and Validation for Clinical Application,
2013.
9 7 Holly A. Massett et al. Assessing the need for a standardized cancer HUman Biobank (caHUB): findings from a national survey with
cancer researchers; JNCI Monographs, Volume 2011, Issue 42, June 2011.
9 8 Specimen Independent Researcher Survey, 2019.
Sources Cited